Wilex reports final Mesupron data

Wilex AG (Xetra:WL6) said 200 and 400 mg daily oral Mesupron plus weekly IV Gemzar gemcitabine led to overall

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE